Stockreport

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF -Enrolled patients allowed to continue on study- MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical compan [Read more]